| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-541 | |
| Phytochemical name or plant extracts | Aloin | |
| PMID | 16357514 | |
| Literature evidence | Author information: (1)Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, Egypt. amyesmat@yahoo.com In the present study the cytotoxic activity of aloin, a natural anthracycline from Aloe plant, is reported against two human breast cancer cell lines, without (MCF-7) and with (SKBR-3) erbB-2-topoIIalpha coamplification. | |
| IUPAC name | (10S)-1,8-dihydroxy-3-(hydroxymethyl)-10-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-10H-anthracen-9-one | |
| Phytochemicals’ class or type of plant extracts | Quinone | |
| Source of phytochemicals or plant Extracts | Aloe vera | |
| Geographical availability | Oman | |
| Plant parts | Leaves | |
| Other cancers | Breast cancer | |
| Target gene or protein | Topo II alpha, Cyclin B1 | |
| Gene or Protein evidence | This was demonstrated by flow cytometric analysis, fluorescence microscopy and western blot analysis, which revealed that aloin at higher concentrations caused a reduction in the proportion of cells undergoing mitosis by induction of apoptosis, inhibition of topo II alpha protein expression and downregulation of cyclin B1 protein expression in MCF-7 cell line, whereas erbB-2 protein expression was not affected. Topo IIalpha protein expression was mildly downregulated in SKBR-3 cell line at higher concentrations only. | |
| Target pathways | NA | |
| IC50 | 60 µg/ml against MCF-7 150 µg/ml against SK-BR-3 | |
| Potency | MCF-7cell line was shown to be more sensitive to aloin than SKBR-3 demonstrated by MTT and clonogenic assays, from which IC50 and 50% ICF values are reported to be 60 microg/ml, respectively, in the former cell line and as high as 150 and 80 microg/ml, respectively, in the latter, which are still far below the maximum tolerated dose of the compound. | |
| Cell line/ mice model | MCF-7, SKBR-3 | |
| Additional information | However, it possesses a more pronounced impact on tumor without erbB-2 and topoIIα coamplification (MCF-7), confirmed with our previous work on other breast cell line (T47D), which necessitates higher doses to attain the same effect produced in a tumor with erbB-2 and topoIIα coamplification (SKBR-3). | |
| PubChem ID | 12305761 | |
| Additional PMIDs | 16357514 32812061 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:530017-1 | |
| Safety | NA |